Company / Operating Cash Flow
Neurogene Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$70.6M
FY2025
5-year range
-$70.6M / -$30.2M
FY2021-FY2025
Trend
-37.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 3 consecutive years, from -$30M in FY2018 to -$71M in FY2025.
Based on SEC 10-K filings.
-$71M in FY2025.
Declined from -$45M to -$71M over the past 6 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Neurogene Inc.'s operating cash flow has declined for 3 consecutive years.
- In FY2025, operating cash flow decreased 37.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.24 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$70.6M | -37.3% |
| FY2024 | -$51.4M | -15.0% |
| FY2019 | -$44.7M | -47.9% |
| FY2018 | -$30.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026